Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $19.3052W HIGH $42.50
Volume
4.57 M
Value Traded
286.25 M
Short % Float
7.69%
Days to Cover
7.9
+2.39%Week
+3.16%1 Month
+10.77%3 Month
+30.15%6 Month
+204.16%5 Year
+185.33%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
26.66 B
EPS (TTM)
-0.37
P/E Ratio
-
Ent. Value
22.82 B
Total Shares
722.32 M
Float Shares
524.29 M
Insiders
27.42%
Institutions
76.39%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ROIV Catalyst Timeline
Dated clinical, regulatory and corporate events for Roivant Sciences Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Roivant Sciences Ltd.
310Total events
15Upcoming
122Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Secondary Endpoint DataBrepocitinibApprovedClinical Data
All key secondary endpoints met in CLARITY-1 and CLARITY-2 (steroid-free quiescence, FA response, macular edema resolution, NEI VFQ-25)
non-infectious uveitissource ↗
●Safety Data UpdateBrepocitinibApprovedClinical Data
Safety profile consistent with prior brepocitinib trials; no new safety signals
non-infectious uveitissource ↗
▲Primary Endpoint MetBrepocitinibApprovedClinical Data
Brepocitinib met primary endpoint (time to treatment failure) in CLARITY-1
non-infectious uveitissource ↗
●R&D DayBrepocitinibApprovedPresentation
Roivant investor call to discuss Phase 3 CLARITY results
non-infectious uveitissource ↗
▼Topline ReadoutIMVT-1402Clinical Data
Topline results from Period 1 of proof-of-concept study of IMVT-1402 in CLE
cutaneous lupus erythematosussource ↗
▼Primary Endpoint MissedIMVT-1402Clinical Data
IMVT-1402 missed primary endpoint of CLASI-A percent change at Week 12 in CLE
cutaneous lupus erythematosussource ↗
▲Safety Data UpdateIMVT-1402Clinical Data
IMVT-1402 demonstrated favorable safety and tolerability profile consistent with prior studies
cutaneous lupus erythematosussource ↗
▲Oral PresentationMosliciguatPresentation
PHocus results presented at ERS International Congress 2026 by Prof. Marc Humbert
Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)source ↗
●Quarterly UpdateCorporate
Roivant investor conference call and webcast to discuss Phase 2 results and Phase 3 initiation
▲Primary Endpoint MetMosliciguatClinical Data
PHocus met primary endpoint with -56.3% placebo-adjusted PVR reduction at Week 16
Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)source ↗
▲Secondary Endpoint DataMosliciguatClinical Data
PHocus met secondary endpoints: +35.2m 6MWD and -53.2% NT-proBNP at Week 16
Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)source ↗
▲Additional DataMosliciguatClinical Data
Exploratory Week 24 results showed continued improvements in 6MWD (+52.7m) and NT-proBNP (-75.9%)
Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)source ↗
▲Trial InitiationMosliciguatTrial
Phase 3 PHrontier study of mosliciguat in PH-ILD initiated
Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)source ↗
◆Topline ReadoutMosliciguatClinical Data
Topline results from Phase 2 PHocus study of mosliciguat in PH-ILD to be presented at ERS Congress 2026
pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
●R&D DayPresentation
Roivant investor conference call and webcast to discuss PHocus results and PHrontier initiation
▲Safety Data UpdateMosliciguatClinical Data
Mosliciguat well tolerated with lower cough incidence vs placebo (12.1% vs 18.2%)
Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)source ↗
●Enrollment UpdateMosliciguatTrial
PHrontier enrollment underway
Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)source ↗
▲FDA ApprovalBrepocitinibApprovedFDA Decision
FDA approved LISRAYA (brepocitinib) for adults with dermatomyositis
dermatomyositissource ↗
▲Product LaunchBrepocitinibApprovedPost-Market
LISRAYA now available in the U.S.
dermatomyositissource ↗
▲First Patient DosedBrepocitinibApprovedTrial
First patients enrolled in Phase 3 BEACON+ study of brepocitinib in CS
cutaneous sarcoidosissource ↗
▲Enrollment UpdateBrepocitinibApprovedTrial
Enrollment in Part 1 of Phase 2b/3 study of brepocitinib in LPP progressing well
lichen planopilarissource ↗
●PublicationBrepocitinibApprovedPresentation
Skin-specific secondary endpoints published in JAMA Dermatology
dermatomyositissource ↗
▲Secondary Endpoint DataBrepocitinibApprovedClinical Data
Skin-specific secondary endpoints published in JAMA Dermatology
dermatomyositissource ↗
▲Full ResultsBrepocitinibApprovedClinical Data
Skin-specific secondary endpoints published in JAMA Dermatology
dermatomyositissource ↗
▲Milestone PaymentCorporate
Genevant and Arbutus received $950 million from Moderna under settlement
◆PDUFA DateBrepocitinibApprovedRegulatory Filing
PDUFA target action date for brepocitinib in DM set for Q3 2026
dermatomyositissource ↗
●IP Litigation RulingIP / Competition
Filed new international lawsuits against Pfizer and BioNTech covering 21 jurisdictions
◆Quarterly UpdateCorporate
Q4 and FY2026 financial results and business update conference call
▲Full ResultsIMVT-1402Clinical Data
Week 16 open-label results: ACR20 72.7%, ACR50 54.5%, ACR70 35.8%
difficult-to-treat rheumatoid arthritissource ↗
▲Breakthrough Therapy DesignationBrepocitinibApprovedDesignation
FDA granted Breakthrough Therapy Designation for cutaneous sarcoidosis
cutaneous sarcoidosissource ↗
▲Enrollment CompleteIMVT-1402Trial
Proof-of-concept trial fully enrolled
cutaneous lupus erythematosussource ↗
▲FDA Filing AcceptedBrepocitinibApprovedRegulatory Filing
FDA accepted NDA with Priority Review
dermatomyositissource ↗
▲Priority ReviewBrepocitinibApprovedRegulatory Filing
FDA granted Priority Review for brepocitinib NDA in DM
dermatomyositis (DM)source ↗
▼Primary Endpoint MissedbatoclimabClinical Data
Phase 3 GO studies of batoclimab in TED failed to meet primary endpoint
thyroid eye diseasesource ↗
▼Topline ReadoutbatoclimabClinical Data
Topline results from Phase 3 GO studies of batoclimab in TED reported
thyroid eye diseasesource ↗
◆Topline ReadoutBrepocitinibApprovedClinical Data
Topline results from Phase 2 trial of brepocitinib in cutaneous sarcoidosis
cutaneous sarcoidosissource ↗
▲Full ResultsBrepocitinibApprovedClinical Data
NEJM publication of Phase 3 VALOR trial results for brepocitinib in dermatomyositis
dermatomyositissource ↗
▲IP Litigation RulingIP / Competition
Genevant and Arbutus enter $2.25B global settlement with Moderna resolving LNP patent infringement claims
COVID-19source ↗
▲FDA Filing AcceptedBrepocitinibApprovedRegulatory Filing
FDA accepts NDA for brepocitinib in dermatomyositis
dermatomyositissource ↗
▲Priority ReviewBrepocitinibApprovedRegulatory Filing
FDA grants Priority Review for brepocitinib NDA
dermatomyositissource ↗
▲Topline ReadoutBrepocitinibApprovedClinical Data
Positive Phase 3 VALOR topline results for brepocitinib in dermatomyositis
dermatomyositissource ↗
▲Trial InitiationBrepocitinibApprovedTrial
Seamless Phase 2b/3 trial of brepocitinib in LPP initiated
lichen planopilarissource ↗
▲First Patient DosedBrepocitinibApprovedTrial
First subjects enrolled in Phase 2b/3 trial of brepocitinib in LPP
lichen planopilarissource ↗
Past FDA Catalysts and PDUFA Decisions
How ROIV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-21 | brepocitinib | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 12%
Mid Cap(rank 82 of 674)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-Q), to Jun 2026)
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mosliciguat Small moleculeNCT06635850 | Pulmonary Hypertension | Phase 3 | ACTIVE NOT_RECRUITING | 531 | Jan 1, 2028 | ||||||
| Brepocitinib Small moleculeNCT06431373 | Uveitis, Posterior | Phase 3 | ACTIVE NOT_RECRUITING | 371 | Feb 1, 2028 | ||||||
| Brepocitinib Small moleculeNCT06978725 | Cutaneous Sarcoidosis | Phase 2/3 | RECRUITING | 168 | Dec 31, 2029 | ||||||
| Brepocitinib Small moleculeNCT07532603 | Lichen Planopilaris | Phase 2/3 | RECRUITING | 342 | Jul 31, 2029 | ||||||
| SP-101 Small moleculeNCT06526923 | Cystic Fibrosis | Phase 1/2 | RECRUITING | 15 | Dec 31, 2026 | ||||||
| Rodatristat Ethyl Small moleculeCompletedNCT04712669 | Pulmonary Arterial Hypertension | Phase 2 | COMPLETED | 108 | Aug 28, 2023 | ||||||
| URO-902 Small moleculeCompletedNCT04211831 | Overactive Bladder With Urge Urinary Incontinence | Phase 2 | COMPLETED | 80 | Jul 20, 2022 | ||||||
| Brepocitinib Small moleculeMarketedNCT06433999 | Dermatomyositis | Approved | COMPLETED | 246 | Feb 28, 2025 | ||||||
| Brepocitinib Small moleculeNot countedNCT05523765 | Non-infectious Intermediate Uveitis | Phase 2 | COMPLETED | 26 | Jul 30, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every ROIV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| brepocitinib BreakthroughPriorityOrphan | non-infectious uveitis | Phase 3 | 2026-10-21 | median treatment failure time of over 48 weeks; 62% of patients on brepocitinib achieved steroid-free quiescence at Week 48; 20% on placebo; 42% of eyes on brepocitinib achieved resolution of macular edema at Week 48; 4.8% on placeboRead More | Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Venker EricOfficer (President & Immunovant CEO) | Sell | -200,000 1,199,154 held | $36.59 | 10/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ROIV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 4.3 % (-4.4 %) | 286.14 M | 8.09 M | -2.41% ( -200.00 K) |
Ownership Trends
ROIV Short Interest
Shares sold short, counted twice a month.
7.69%
Short % of Float
of tradable shares sold short
40.3M
Shares Sold Short
+2.6% vs prior count
7.9 High
Days to Cover
trading days of normal volume to buy every short share back
5.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ROIV ranks across every disease it competes in
Competitive Position is a premium feature
See how ROIV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialROIV News
ROIVRoivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift
Roivant Social Ventures (RSV) announced a six-figure donation to No Patient Left Behind (NPLB) to enhance drug affordability and access. This partnership aims to support ongoing medical innovation while RSV concludes its institutional work. NPLB will carry on RSV's legacy by focusing on improving healthcare equity and affordability for patients.
Read more →ROIV▲ +5.4%on this news
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Roivant announced it will host a conference call on November 9, 2026, to report its financial results for Q2 2026 and provide a business update. The company is also preparing for an investor day on December 9, 2026. Roivant is focused on developing innovative therapies, including LISRAYA™ and IMVT-1402.
Read more →ROIV▲ +5.4%on this news
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
Roivant and Priovant announced positive results from the Phase 3 CLARITY trials for brepocitinib in non-infectious uveitis. The drug achieved significant benefits on primary and secondary endpoints, including a median treatment failure time of over 48 weeks. Priovant plans to file a supplemental New Drug Application in 2027.
Read more →ROIVRoivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Roivant announced that Immunovant's proof-of-concept study for IMVT-1402 in cutaneous lupus erythematosus did not meet its primary endpoint of statistical significance. Despite observing positive trends and a favorable safety profile, the company will discontinue development in this indication due to the competitive landscape. Other clinical timelines for IMVT-1402 remain on track.
Read more →ROIV▲ +18.8%on this news
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
Pulmovant announced positive results from the Phase 2 PHocus study of mosliciguat, showing a significant reduction in pulmonary vascular resistance (PVR) and improvements in six-minute walk distance and NT-proBNP levels. The drug was well tolerated, and a Phase 3 study, PHrontier, has been initiated to further evaluate its efficacy in patients with pulmonary hypertension associated with interstitial lung disease.
Read more →ROIV▲ +18.8%on this newsshared move
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
Roivant announced that it will present topline results from the Phase 2 PHocus study of mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the ERS Congress 2026. The presentation will take place on September 8, 2026, by Dr. Marc Humbert. An investor call will also be hosted on the same day to discuss the findings.
Read more →ROIVRoivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Roivant has announced the FDA approval of LISRAYA™ (brepocitinib) for adults with dermatomyositis, marking a significant advancement in treatment options. This once-daily pill targets immune pathways involved in the disease and has shown robust efficacy in clinical trials. LISRAYA is now available in the U.S., with support programs to assist eligible patients in accessing the medication.
Read more →ROIVJAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
The Phase 3 VALOR trial results for brepocitinib, published in JAMA Dermatology, show significant improvements in skin-specific outcomes for patients with dermatomyositis. Patients treated with brepocitinib 30 mg experienced rapid and durable enhancements in disease activity, itch, and quality of life. Notably, many patients achieved remission-level outcomes by Week 52, indicating brepocitinib's potential as a key treatment option.
Read more →ROIVPriovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
Priovant has enrolled the first patients in the Phase 3 BEACON+ study of brepocitinib for cutaneous sarcoidosis, following its positive Phase 2 results. This investigational therapy has received FDA Breakthrough Therapy Designation and aims to address the significant unmet need in this condition. The study will evaluate the efficacy of brepocitinib against placebo in 140 patients, with topline results expected in 2028.
Read more →ROIVRoivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
Roivant reported its financial results for Q1 2026, highlighting progress in clinical preparations for brepocitinib, with a launch expected by September 2026. The company also noted strong enrollment in ongoing studies and a solid cash position of $3.9 billion. However, it faced a net loss of $290.6 million during the quarter, alongside rising R&D expenses.
Read more →ROIVRoivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Roivant will host a live conference call on August 6, 2026, to discuss its financial results for Q1 ended June 30, 2026, and provide a business update. The event will be accessible via phone and webcast, with details available on Roivant's website. The company is focused on developing innovative therapies for various conditions.
Read more →ROIV▲ +14.9%on this news
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
Roivant reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, highlighting promising clinical data for IMVT-1402 in rheumatoid arthritis and brepocitinib's Breakthrough Therapy Designation for cutaneous sarcoidosis. The company anticipates a commercial launch of brepocitinib in dermatomyositis by September 2026 and has a robust cash position of $4.3 billion. However, R&D expenses have increased significantly, reflecting ongoing investments in their pipeline.
Read more →ROIVRoivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
Roivant has announced a live conference call scheduled for May 20, 2026, to report its financial results for the fourth quarter and fiscal year ending March 31, 2026. The call will also provide a business update. Roivant's pipeline includes several innovative therapies targeting various autoimmune conditions and pulmonary hypertension.
Read more →ROIVPriovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
Priovant has launched a new Phase 2b/3 clinical trial for brepocitinib targeting lichen planopilaris (LPP), a severe inflammatory scalp disorder. This trial marks the fourth indication for brepocitinib, which has shown promising results in previous studies. The FDA has granted Priority Review for brepocitinib's NDA for dermatomyositis, with further developments expected in other indications.
Read more →ROIVRoivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Roivant has launched a new Phase 2b/3 trial for brepocitinib targeting lichen planopilaris (LPP), a severe inflammatory scalp disorder. This marks the fourth indication for brepocitinib, which has shown promising results in prior studies. Meanwhile, Immunovant reported that its Phase 3 studies for batoclimab in thyroid eye disease did not meet their primary endpoint. An investor call is scheduled to discuss these developments.
Read more →ROIVNew England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
Priovant Therapeutics announced positive results from the Phase 3 VALOR trial of brepocitinib for dermatomyositis, published in the New England Journal of Medicine. The trial met its primary endpoint, showing significant improvement in Total Improvement Score and enabling corticosteroid reduction. Despite some increased serious infections, the findings suggest a potential shift in treatment paradigms for dermatomyositis.
Read more →ROIVPriovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
Priovant Therapeutics announced that the FDA has accepted its New Drug Application for brepocitinib, a potential treatment for dermatomyositis, and granted it Priority Review. The application is supported by positive results from the Phase 3 VALOR study, which showed significant improvements in patient outcomes. If approved, brepocitinib would be the first targeted therapy for this condition, with a launch anticipated by September 2026.
Read more →ROIVRoivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
Roivant announced a $2.25 billion global settlement between Genevant Sciences and Arbutus Biopharma with Moderna. The agreement resolves patent infringement claims over LNP delivery technology used in Moderna's COVID-19 vaccines. Moderna will pay $950 million upfront and an additional contingent payment of $1.3 billion based on legal outcomes. This settlement supports Genevant's ongoing litigation efforts and validates their intellectual property, enhancing financial stability for future investments.
Read more →ROIV▲ +22.1%on this news
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
Priovant Therapeutics announced positive Phase 2 results for brepocitinib in treating cutaneous sarcoidosis, marking a significant advancement in a field lacking approved therapies. The BEACON study demonstrated meaningful clinical improvements in patients compared to placebo, with high response rates and a favorable safety profile. The company plans to initiate a Phase 3 program in 2026.
Read more →ROIV▲ +22.1%on this news
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
Roivant Sciences reported positive Phase 2 results for brepocitinib in cutaneous sarcoidosis, showing a 22.3-point improvement in disease activity scores versus placebo. The company also announced a 4.5 billion dollar cash balance as of the end of the third quarter. Priovant plans to start a Phase 3 study for the drug in 2026 following FDA engagement. Roivant submitted a new drug application for brepocitinib in dermatomyositis during this period.
Read more →About Roivant Sciences Ltd.
Headquarters7TH FLOOR, 50 BROADWAY, LONDON, SW1H 0DB
BIOPHARMAWATCH ELITE PLUS
Trade the next ROIV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime